Nosocomial Infections Due to Multidrug Resistant Pseudomonas Aeruginosa

Pseudomonas aeruginosa is a leading cause of nosocomial infections.  The rise of emergence of antibiotic resistance may vary with different antibiotic treatments.  To compare the risks of emergence of resistance associated with panel of antibiotics used in the treatment of nosocomial infection, a case study was conducted.  A total of 120 P. aeruginosa isolates were recovered from lower respiratory tract (38.0%), blood stream (13.0%), infected wounds (22.0%), and urinary tract infections (27.0%). The clinical isolates were tested for antibiotics susceptibility and showed variation in their sensitivity, 8.0% of the isolates were resistant to Imipenem, 11.0% to Amikacin, 16.0% to Ciprofloxacin, 20.0% to Gentamycin, 25.0% for both Ceftazidim and Aztreonam, 33.0% to Piperacillin, 35.0% to Tobramycin, 75.0% to Ceftriaxon, 80.0% to Amoxicillin/clavulanic acid, and 100% of the isolates were resistant to Ampicillin.  The multidrug resistance test (resistance to at least three of the drugs Ceftazidim, Ciprofloxacin, Gentamycin, and Imipenem) showed that 40.0% of the isolates were considered as multidrug resistant.  These strains distributed as 39.0% of the isolates recovered from lower respiratory tract, 44.0% from blood stream, 37.0% from wound infections, and 42.0% of the strains isolated from urinary tract infections.  Greater decreases in susceptibility rates were, however, observed for Fuoroquinolones and Ceftazidim among P. aeruginosa isolates.

Key ward: Pseudomonas aeruginosa, Nosocomial infection, Multidrug resistance